Research advances in sodium taurocholate cotransporting polypeptide in hepatobiliary diseases
10.3969/j.issn.1001-5256.2022.05.043
- VernacularTitle:钠牛磺胆酸共转运多肽在肝胆疾病中的研究进展
- Author:
Xiaoqiang GAO
1
;
Shi ZUO
2
;
Xiaodong JIA
3
;
Yinying LU
3
Author Information
1. Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China;Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
2. Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China
3. Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China
- Publication Type:Reviews
- Keywords:
Hepatitis, Viral, Human;
Non-alcoholic Fatty Liver Disease;
Liver Cirrhosis;
Liver Cirrhosis, Biliary;
Carcinoma, Hepatocellular;
Sodium Taurocholate Co-transporting Polypeptide
- From:
Journal of Clinical Hepatology
2022;38(5):1179-1182
- CountryChina
- Language:Chinese
-
Abstract:
Sodium taurocholate cotransporting polypeptide (NTCP) is not only an important transporter for bile acid absorption into the liver, but also a functional receptor for HBV and HDV, and extensive studies have been performed for its structure, function, gene characteristics, and expression and regulation mechanisms. NTCP is also associated with chronic viral hepatitis, nonalcoholic fatty liver disease, liver fibrosis, primary biliary cholangitis, and hepatocellular carcinoma. This article elaborates on the role of NTCP in various hepatobiliary diseases, so as to provide new direction for the diagnosis and treatment of related diseases.
